Quality Control: Each batch of HRE GFP Reporter Vector (HR-GFP) is verified for plasmid DNA purity and sequence integrity by spectrophotometry and Sanger sequencing. Functional validation is performed by transient transfection in HEK293T cells followed by HIF-1 pathway activation using CoCl₂ (300 μM, 24h). Inducible GFP expression is confirmed by fluorescence microscopy. (Figure 1A).
Product Use: HR-GFP is for research use only and is not approved for human or animal use, or application in clinical or in vitro diagnostic procedures.
Shipping and Storage: The product is shipped at room temperature. Upon receipt, store at -20°C.
References: [1] Shibata, T., Giaccia, A. J., & Brown, J. M. (2000). Development of a hypoxia-responsive vector for
tumor-specific gene therapy. Gene Therapy, 7(7), 493–498.
[2] Vordermark, D., Shibata, T., & Brown, J. M. (2001). Green fluorescent protein is a suitable reporter of
tumor hypoxia despite an oxygen requirement for chromophore formation. Neoplasia, 3(6), 527–534.
[3] Wang, L., et al. (2024). Hypoxia-responsive HRE-GFP reporter system for monitoring tumor hypoxia
and evaluating HIF-targeted gene therapy. Journal of Cancer, 15(14), 4345–4356.